The VE-cadherin binding domain of fibrinogen induces endothelial barrier permeability and enhances transendothelial migration of malignant breast epithelial cells

International Journal of Cancer

Volumn 125, Issue 3, 2009, Pages 577-584

  Sahni, Abha ^a   Aŕevalo, Maria T ^a   Sahni, Sanjeev K ^a,b   Simpson Haidaris, Patricia J ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Endothelial permeability; Fibrinogen; Inflammatory breast cancer; Metastasis

Indexed keywords

ANTIBODY; FIBRINOGEN; VASCULAR ENDOTHELIAL CADHERIN;

ARTICLE; BETA CHAIN; BINDING AFFINITY; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MICROVASCULARIZATION; MOLECULAR INTERACTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; UMBILICAL VEIN;

ANTIGENS, CD; BREAST NEOPLASMS; CADHERINS; CELL MEMBRANE PERMEABILITY; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOGEN; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MICROCIRCULATION; MICROSCOPY, CONFOCAL; NEOVASCULARIZATION, PATHOLOGIC; UMBILICAL VEINS;

EID: 67650095394     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24340     Document Type: Article

References (48)

1. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007;110:1723-9.
2. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 2001;936:406-25.
3. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302-9.
4. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002;62:6966-72.
5. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178-85.
6. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
7. van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 2001;936:426-37.
8. Clark RAF. The molecular and cellular biology of wound repair, 2 edn. New York: Plenum Press, 1996.
9. 15-42 primary structure. Blood Coagul Fibrinolysis 1994;5:487-96.
10. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-904.
11. Odrljin TM, Francis CW, Sporn LA, Bunce LA, Marder VJ, Simpson-Haidaris PJ. Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vasc Biol 1996;16:1544-51.
12. 15-42 of the β chain. J Clin Invest 1992;89:842-50.
13. Sporn LA, Bunce LA, Francis CW. Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. Blood 1995;86:1802-10.
14. Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW. Fibrinogen synthesized by cancer cells augments the proliferative effect of FGF-2. J Thromb Haemost 2008;6:176-83.
15. Bach TL, Barsigian C, Chalupowicz DG, Busler D, Yaen CH, Grant DS, Martinez J. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res 1998;238: 324-34.
16. Chalupowicz DG, Chowdhury ZA, Bach TL, Barsigian C, Martinez J. Fibrin II induces endothelial cell capillary tube formation. J Cell Biol 1995;130:207-15.
17. 2-terminal portions of the fibrin β chains. Biochemistry 2002;41: 4107-16.
18. 15-42 sequence of fibrin. J Biol Chem 1998;273:30719-28.
19. Rybarczyk BJ, Lawrence SO, Simpson-Haidaris PJ. Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. Blood 2003;102:4035-43.
20. 15-42 protects the myocardium against ischemiareperfusion injury. Nat Med 2005;11:298-304.
21. Zacharowski K, Zacharowski P, Reingruber S, Petzelbauer P. Fibrin (ogen) and its fragments in the pathophysiology and treatment of myocardial infarction. J Mol Med 2006;84:469-77.
22. 15-42 is cardioprotective in a pig model of myocardial ischemiareperfusion injury. Crit Care Med 2007:1730-5.
23. 15-42 in acute and chronic rodent models of myocardial ischemia-reperfusion. Shock 2007;27:631-7.
24. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982;95:355-60.
25. Adriance MC, Inman JL, Petersen OW, Bissell MJ. Myoepithelial cells: good fences make good neighbors. Breast Cancer Res 2005;7: 190-7.
26. Sahni A, Odrljin T, Francis CW. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem 1998;273:7554-9.
27. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000;96:3772-8.
28. Sahni A, Sahni SK, Simpson-Haidaris PJ, Francis CW. Fibrinogen binding potentiates FGF-2 but not VEGF induced expression of u-PA, u-PAR, and PAI-1 in endothelial cells. J Thromb Haemost 2004;2: 1629-36.
29. Guadiz G, Sporn LA, Simpson-Haidaris PJ. Thrombin cleavage-independent deposition of fibrinogen in extracellular matrices. Blood 1997;90:2644-53.
30. Languino LR, Plescia J, Duperray A, Brian AA, Plow EF, Geltosky JE, Altieri DC. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 1993;73: 1423-34.
31. Saito M, Shima C, Takagi M, Ogino M, Katori M, Majima M. Enhanced exudation of fibrinogen into the perivascular space in acute inflammation triggered by neutrophil migration. Inflamm Res 2002; 51:324-31.
32. Simpson-Haidaris PJ. Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells. Blood 1997;89:873-82.
33. Rybarczyk BJ, Simpson-Haidaris PJ. Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Cancer Res 2000;60:2033-9.
34. Duan HO, Simpson-Haidaris PJ. Cell type-specific differential induction of the human gamma-fibrinogen promoter by IL-6. J Biol Chem 2006;281:12451-7.
35. Lawrence SO, Simpson-Haidaris PJ. Regulated de novo biosynthesis of fibrinogen in extrahepatic epithelial cells in response to inflammation. Thromb Haemost 2004;92:234-43.
36. Nguyen MD, Simpson-Haidaris PJ. Cell type-specific regulation of fibrinogen expression in lung epithelial cells by dexamethasone and IL-1b. Am J Respir Cell Mol Biol 2000;22:209-17.
37. Guadiz G, Sporn LA, Goss RA, Lawrence SO, Marder VJ, Simpson-Haidaris PJ. Polarized secretion of fibrinogen by lung epithelial cells. Am J Respir Cell Mol Biol 1997;17:60-9.
38. Dahl M. Networking with fibrinogen: a prerequisite for fibroblast growth factor-2 (FGF-2)-stimulated tumor growth? J Thromb Haemost 2008;6:174-5.
39. Dvorak HF. Angiogenesis: update 2005. J. Thromb. Haemost. 2005;3: 1835-42.
40. Dvorak HF. Discovery of vascular permeability factor (VPF). Exp Cell Res 2006;312:522-6.
41. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9.
42. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 2003;8:141-8.
43. Kleer CG, Zhang Y, Merajver SD. CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs 2007;185:95-9.
44. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer. Breast Cancer Res Treat 2007;102:129-35.
45. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56.
46. Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol 1998;28:740-4.
47. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prove A, Lemmens J, Vermeulen P. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002;86:389-95.
48. Berger FG. The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res Treat 2004;88:281-5.